On March 19 the FDA approved a higher-dose version of the weight-loss drug Wegovy. Branded as Wegovy HD, the new formulation delivers 7.2 mg of semaglutide by weekly injection, up from the prior 2.4 mg weekly dose.
Why the higher dose
Novo Nordisk pursued the 7.2 mg dose after trials showed some people did not reach therapeutic goals on 2.4 mg. In the 2025 STEP UP phase 3b trial, participants taking 7.2 mg lost an average of 18.7% of body weight, and roughly one in three lost at least 25%. The FDA said approval was supported by clinical data showing a safety profile consistent with previously known effects of semaglutide.
Clinical perspective and safety monitoring
Some clinicians are cautiously optimistic. Meghan Garcia-Webb, MD, who did not participate in the trial, noted that trial data showed slightly fewer serious adverse events in the 7.2 mg group, but emphasized that real-world monitoring will be key as broader populations begin treatment. The FDA commissioner also highlighted expedited review of products tied to national priorities.
Common side effects and dose-related issues
The most frequent adverse effects with Wegovy are gastrointestinal and dose-related. Common symptoms include nausea, diarrhea, constipation, vomiting, and abdominal pain. Patients may also experience headache, dizziness, fatigue, bloating or gas, heartburn, and upper-respiratory symptoms such as a runny nose or sore throat. People with type 2 diabetes may have episodes of low blood sugar.
Higher doses have been associated with more reports of altered skin sensations—sensitivity, pain, or burning. It’s common for people to have a temporary flare of side effects when a dose is increased; these usually improve over weeks to months or with dose reduction.
Eye safety signal to watch
Recent research and adverse-event reports have raised concern about a possible increased risk of ischemic optic neuropathy (ION, sometimes called an “eye stroke”) with higher semaglutide exposures, especially in males. ION can cause sudden vision loss; investigators have suggested the risk may relate to higher systemic drug exposure and rapid weight loss altering optic nerve blood flow. Because FDA adverse-event reporting is voluntary, the true incidence is uncertain. Clinicians are advised to monitor vision and consider ophthalmology evaluation for patients with pre-existing eye disease or symptoms. Garcia-Webb recommends an eye check before starting high-dose semaglutide when there are preexisting eye concerns.
Wegovy’s listed common side effects
– Nausea, upset stomach, or vomiting
– Diarrhea or constipation
– Headache or dizziness
– Stomach pain
– Fatigue
– Bloating, belching, or gas
– Heartburn
– Runny nose or sore throat
– Low blood sugar in people with type 2 diabetes
What to discuss with your clinician
Most side effects are mild and resolve over time; persistent or bothersome symptoms should be discussed with a healthcare professional. Other practical considerations include the cost of therapy and the likelihood that ongoing treatment will be needed to maintain weight loss and its associated health benefits. If you or your clinician are considering Wegovy HD, weigh the greater efficacy seen in trials against potential dose-related side effects and the need for closer monitoring, especially of vision and other preexisting conditions.
